{"id":218461,"date":"2026-04-13T09:51:54","date_gmt":"2026-04-13T07:51:54","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=218461"},"modified":"2026-04-13T10:46:51","modified_gmt":"2026-04-13T08:46:51","slug":"boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/","title":{"rendered":"Boehringer Ingelheim introduces LENZELTA\u00ae: A new vaccine advancing mastitis prevention in dairy cows"},"content":{"rendered":"<p>Statement issued by the company (Announcement)<\/p>\n<div>\n<ul>\n<li>LENZELTA<sup>\u00ae<\/sup> is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers<sup>1<\/sup>.\u00a0Administration is simple with two doses during the dry-off period.<\/li>\n<li>Mastitis continues to be one of the most pressing challenges for dairy farmers and livestock veterinarians worldwide, impacting the health of cows, while also posing an economic burden on dairy farms.<\/li>\n<li>LENZELTA<sup>\u00ae<\/sup> offers the earliest onset of immunity and longest lasting protection of bovine mastitis vaccines against the two key pathogens\u00a0<em>S. aureus<\/em>\u00a0and\u00a0<em>E. coli<\/em><sup>2<\/sup>.<\/li>\n<\/ul>\n<p>With the launch of\u00a0<strong>LENZELTA<\/strong><sup>\u00ae<\/sup>, <strong>Boehringer Ingelheim<\/strong> enhances its comprehensive <strong>mastitis<\/strong> portfolio, offering <strong>farmers<\/strong> and <strong>veterinarians<\/strong> effective solutions to keep their dairy cattle healthy and farms viable. The vaccine will be available in several countries in the European Union (EU) as of April 2026.<\/p>\n<p>Mastitis is among the most widespread and economically significant diseases in dairy cattle. It affects udder health, reduces milk quality and quantity, leading to substantial production losses. For many dairy farms, mastitis-related costs represent one of the highest avoidable economic impacts in their herds<sup>3<\/sup>. As cows are particularly vulnerable around calving, preventive strategies during the dry\u2011off period play a crucial role in maintaining herd health and well-being and ensuring a smooth transition into lactation.<\/p>\n<h2>A new preventive tool for veterinarians and farmers<\/h2>\n<p>LENZELTA<sup>\u00ae<\/sup> targets two key mastitis pathogens,\u00a0<em>S. aureus<\/em>\u00a0and\u00a0<em>E. coli<\/em>, supporting farmers and veterinarians in tackling infections proactively. By focusing on prevention at a critical stage of the lactation cycle, the vaccine helps create more stable conditions for milk production and animal well\u2011being.<\/p>\n<p>LENZELTA<sup>\u00ae<\/sup> is administered in two doses during the dry\u2011off period, making it easy to integrate into established herd\u2011health routines. The timing supports an early onset of immunity and provides protection lasting up to six months, covering the period in which cows are most susceptible to mastitis<sup>4<\/sup>. The vaccine uses an oil\u2011free adjuvant and is available in multiple vial sizes, offering veterinarians flexibility in day\u2011to\u2011day practice.<\/p>\n<p>For veterinarians, LENZELTA<sup>\u00ae<\/sup> offers a practical way to manage mastitis proactively. It supports a preventive approach and enables more sustainable care for dairy herds.<\/p>\n<p>For farmers, LENZELTA<sup>\u00ae<\/sup> can give them back a sense of control, confidence and peace of mind by reducing the prevalence and impact of mastitis infections. The vaccine supports healthier cows, can help strengthen herd productivity and contribute to more reliable milk production and farm operations.<\/p>\n<p>\u201cWith LENZELTA<sup>\u00ae<\/sup>, we are setting a new benchmark in mastitis prevention,\u201d says Dr. Gerald Behrens, Head of Ruminants at Boehringer Ingelheim. \u201cMastitis places a massive burden on dairy farms around the world. By offering a highly effective vaccine that is easy to integrate into existing routines, we give farmers and veterinarians a powerful new tool to manage one of the industry\u2019s most persistent challenges.\u201d<\/p>\n<p>Starting in April, LENZELTA<sup>\u00ae<\/sup> will be available in several countries across the EU.<\/p>\n<h2>References<\/h2>\n<p><sup>1<\/sup>\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liEcrguBcaPU-x3dC3jACbjT5D6DM_NqY0OlGRznmHEvz7BYxA4PKdTB4X3dDBPnYaJldetQVcEAxhANulOt2HlaLtRUffSeeJlZnjWupNR6QWnTRodU4ZIlZAM5I8H6KfgAHC2XP5wkVAMXd4cJOEgtY1YlVsMDGeM9x59cZG06DfI0chuid4ATagz1Aqx0jqVBO5p3UBke6VYrmwC-wJMau7XkXdiSK10HEL-xPLw=\" target=\"_blank\" rel=\"noopener\">Lenzelta, Suspension for injection | UPD<\/a><\/p>\n<p><sup>2<\/sup>\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=stDyqZUqq8TPSnW7oS-nzjtcW_-dntUcbsl8fUDwaXxMHphgGYrANpBlQiwY4Qf1DcwO0q18fh71Pqn1UAvI8oQtk4qiLX_r8HxKv3e4I8GF6eGqZk6O4EKH6NqoLKC7fdt88YU4N9_3zW7djnR0SR7db5BNee_6AGjso8X6Sd2U-PBecrDczm0M3ERY6sLm2vfGZgRjEVvgLqha0p7yXOtsNT-hjd1hvn7DUBrmunSuqdjqOSf8avUwom_jKrQO\" target=\"_blank\" rel=\"noopener\">noahcompendium.co.uk\/?id=-452828<\/a><\/p>\n<p><sup>3<\/sup>\u00a0Stanek P.,\u00a0\u017b\u00f3\u0142kiewski P., Janu\u015b E. A review on mastitis in dairy cows research: Current status and future perspectives. Agriculture. 2024; 14(8):1292.<br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QSJDrZRagKb_P6YEzmeo-ohBrqlVYdPoUej9Ffn2SWT2ncoYEbUy3y44TB8fqaFV6XIcFI50XkE-wRMb641ikj_ks5em0siP4Yd6VhOKBOKigAfmAhLmISSgqJGursMSxvz9_isEozVmZIUHvPfdPQ6UqnzxNx5d4QrBaByGDTugnsMGO5_e1DEQhbhVRYhuCve-ZfhIDwT_yvEb7FSRq77Bw0SZzDQIXP-ch2k0XSF9XomGVfo9q2lE55lgfLq5\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.3390\/agriculture14081292<\/a><\/p>\n<p><sup>4<\/sup>\u00a0Puerto M.A., Shepley E., Cue R.I., Warner D., Dubuc J., Vasseur E. The hidden cost of disease: Impact of the first incidence of mastitis on production and economic indicators of primiparous dairy cows. Journal of Dairy Science, Volume 104, Issue 7, 7932 \u2013 7943<br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QSJDrZRagKb_P6YEzmeo-ohBrqlVYdPoUej9Ffn2SWRmxjcPfdgF6ZgyavyXFtBdgLyB5tEqIEu-sGRrR9MtbqOBDe_fYT9h-c7iklsB8p61M6ODafyoZDt-qJRemqQQvZtLkER_uHzfdk56bdzswP4fWuCPGUvMJz3Ry2a2MOXdzAqRQQpsoU_Y6NneJ3pqqXOoWeolt_u-R2qQo5pHyHm8IvyvU4OG6Ssyq3TyrkGS1rKXuDSq9dFY7su08m7B\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.3168\/jds.2020-19584<\/a><\/p>\n<h2>Boehringer Ingelheim &#8211; Animal Health business<\/h2>\n<p>Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fV0wIu1nc7xciB58Z6BwIpdBy9Lk1d9M2ad3a2YXaD4JYkWYBCQvgjG7cYaz1ueI7nv3q0nDAIs-OWhAeips0Nrb053XLYWluOGyeFtn8OoTG1i6zzo2-TWgG0V4KcEe4XhAasdfRY_nKAVRLAsNfKZpL2dhD7Sa8vTEulOFnEk=\" target=\"_blank\" rel=\"noopener\">www.boehringer-ingelheim.com\/animal-health<\/a>.<\/p>\n<h2>Boehringer Ingelheim<\/h2>\n<p>Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry\u2019s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fV0wIu1nc7xciB58Z6BwIpdBy9Lk1d9M2ad3a2YXaD6ChvuoQn7XNxzAqshGVCQlWWQP49Qyr0CpSolXty5hSZq33FN72Fbm0kcovfGxPzqy4VNaxgROrwEDn95CnoZ5\" target=\"_blank\" rel=\"noopener\">www.boehringer-ingelheim.com<\/a>.<\/p>\n<h2>Intended Audiences Notice<\/h2>\n<p>This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.<\/p>\n<p><em>AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Statement issued by the company (Announcement) LENZELTA\u00ae is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers1.\u00a0Administration is simple with two doses [&hellip;]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[125518],"tags":[],"class_list":["post-218461","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Boehringer Ingelheim introduces LENZELTA<\/title>\n<meta name=\"description\" content=\"With LENZELTA\u00ae, Boehringer Ingelheim enhances its comprehensive mastitis portfolio, offering farmers and veterinarians effective solutions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim introduces LENZELTA","description":"With LENZELTA\u00ae, Boehringer Ingelheim enhances its comprehensive mastitis portfolio, offering farmers and veterinarians effective solutions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"Boehringer Ingelheim introduces LENZELTA\u00ae: A new vaccine advancing mastitis prevention in dairy cows","datePublished":"2026-04-13T07:51:54+00:00","dateModified":"2026-04-13T08:46:51+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/"},"wordCount":865,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","articleSection":["Globenewswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/","url":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/","name":"Boehringer Ingelheim introduces LENZELTA","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2026-04-13T07:51:54+00:00","dateModified":"2026-04-13T08:46:51+00:00","description":"With LENZELTA\u00ae, Boehringer Ingelheim enhances its comprehensive mastitis portfolio, offering farmers and veterinarians effective solutions.","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/boehringer-ingelheim-introduces-lenzelta-a-new-vaccine-advancing-mastitis-prevention-in-dairy-cows\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim introduces LENZELTA\u00ae: A new vaccine advancing mastitis prevention in dairy cows"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-UPz","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/218461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=218461"}],"version-history":[{"count":3,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/218461\/revisions"}],"predecessor-version":[{"id":218479,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/218461\/revisions\/218479"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=218461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=218461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=218461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}